Conclusion
Our study demonstrated that the use of MTX resulted in liver tissue damage, leading to both biochemical and histopathological changes. However, RAN may be a promising alternative agent by activating the antioxidant mechanism and suppressing the ROS mechanism in the liver. RAN is a new antianginal agent with an antioxidant mechanism that warrants further investigation. To our knowledge, this is the first study to investigate the role of RAN in preventing and treating MTX-induced liver damage. Our findings suggest that RAN may be a potential hepatoprotective agent for future clinical applications.